Gsk (GSK) Non-Current Assets (2009 - 2026)

Gsk (GSK) has 18 years of Non-Current Assets data on file, last reported at $59.3 billion in Q2 2026.

• For the quarter ending Q2 2026, Non-Current Assets rose 6.85% year-over-year to $59.3 billion; the trailing twelve-month figure through Jun 2026 stood at $59.3 billion (up 6.85% YoY), and the FY2025 full-year result was $58.0 billion, up 6.86% from the prior year.
• Non-Current Assets was $59.3 billion for Q2 2026 at Gsk, down from $60.8 billion in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $60.8 billion in Q1 2026 to a low of $39.9 billion in Q1 2022.
• A 5-year average of $51.8 billion and a median of $52.3 billion in 2024 frame the typical range for Non-Current Assets.
• Across the five-year window, Non-Current Assets sank 51.43% in 2022 and increased 18.48% in 2023, its largest moves.
• Gsk's Non-Current Assets stood at $46.2 billion in 2022, then advanced by 8.46% to $50.1 billion in 2023, then rose by 8.81% to $54.5 billion in 2024, then rose by 6.42% to $58.0 billion in 2025, then advanced by 2.19% to $59.3 billion in 2026.
• Per Business Quant data, the three most recent Non-Current Assets figures were $59.3 billion in Q2 2026, $60.8 billion in Q1 2026, and $58.0 billion in Q4 2025.